ClinicalTrials.gg
CompletedNCT04733040NewPLACEUpdated Feb 7, 2025

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

A Phase 2 interventional study of MOR202 in Glomerulonephritis, Membranous Nephropathy and antiPLA2R Positive, sponsored by HI-Bio, A Biogen Company. Completed at 25 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Primary conditionGlomerulonephritis, MembranousRegistry: GlomerulonephritisReclassifiedWhy we changed it
Registry
Glomerulonephritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glomerulonephritis, Membranous
Why
  1. The study's listed conditions name Glomerulonephritis, Membranous, a narrower term within Glomerulonephritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy, safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy

Read the detailed description

After treatment, subjects will enter a repeat treatment period (3 months) if necessary; and a final follow-up period of 15 to 18 months.

Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.

02

Conditions studied

  • Glomerulonephritis
  • Membranous Nephropathy
  • antiPLA2R Positive

Browse trials for

03

In context

Glomerulonephritis, Membranous Reclassified

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

This study's enrollment of 24 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.

Browse Glomerulonephritis, Membranous studies →

Lead sponsor

HI-Bio, A Biogen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

First submitted before HI-Bio became part of Biogen.

Compared within Glomerulonephritis, Membranous, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glomerulonephritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects ≥ 18 to ≤ 80 years (at date of signing the form [ICF]).
  • Urine protein to creatinine ratio (UPCR) of ≥ 3.0 g/g or proteinuria ≥ 3.5 g/24 h
  • Estimated (eGFR) ≥ 50 ml/min/1.73 m² (eGFR >30 and \< 50 ml/min/1.73 m² can be included provided an interstitial fibrosis and tubular atrophy (IFTA) score of \< 25% in a kidney )
  • Not in spontaneous remission despite proper treatment with angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. If the subject is intolerant to ACEI and ARBs, the reason must be documented and approval for enrollment be obtained from the Medical Monitor.
  • Systolic blood pressure (BP) ≤150 mmHg and diastolic BP ≤100 mmHg after 5 minutes of rest.
  • Serum anti-PLA2R antibodies ≥ 50.0 RU/mL determined by Euroimmun ELISA.
  • Female subjects: A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a female of (FCBP)
    2. A FCBP who agrees to follow the guidance during the treatment period and for at least 3 months after the last dose of MOR202

Key Exclusion Criteria:

  • \< 80 g/L.
  • Thrombocytopenia: \< 100.0 x 10\^9/L.
  • Neutropenia: Neutrophils \< 1.5 x 10\^9/L.
  • Leukopenia: Leukocytes \< 3.0 x 10\^9/L.
  • Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L.

Subjects may receive supportive therapies to meet the above criteria

  • B-cells \< 5 x 10\^6/L
  • Diabetes mellitus type 2: Subjects with type 2 diabetes mellitus may only enter the clinical trial if a kidney biopsy performed within 6 months prior to screening shows MN without evidence of diabetic nephropathy and diabetes is controlled, as shown by:

    1. (HbA1c) \<8.0 % or 64 mmol/mol.
    2. No diabetic retinopathy known.
    3. No peripheral neuropathy known.
  • Total , or alanine aminotransferase >1.5 x , alkaline phosphatase >3.0 x ULN.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    MOR202 5 Doses

    5 doses administered on Day 1, 8, 15, 29, and 57

    Drug: MOR202

  • Experimental
    MOR202 2 Doses

    2 doses administered on Day 1 and 15

    Drug: MOR202

Interventions

  • DrugMOR202

    MOR202 will be administered as an intravenous infusion

    Also known as: Felzartamab

06

What researchers measure

Primary outcomes

  1. efficacy: percent change of anti-PLA2R antibody levels

    efficacy of 2 different dosing regimens of MOR202 in subjects with anti-PLA2R antibody positive MN

    Time frame: 3 months compared to baseline

Secondary outcomes

  1. efficacy: immunological complete response (ICR) rate

    efficacy of 2 different dosing regimens of MOR202

    Time frame: ICR rate at 3 months, 6 months, 12 months and 24 months

  2. efficacy: overall proteinuria response (OPR) rate

    efficacy of 2 different dosing regimens of MOR202

    Time frame: OPR rate at 6 months, 12 months and 24 months.

  3. safety: determined by the frequency, incidence and severity of TEAEs

    frequency, incidence and severity of treatment-emergent adverse events

    Time frame: through treatment completion, an average of 3 months per treatment period

  4. PK profile

    MOR202 serum concentrations after multiple i.v. administrations

    Time frame: through study completion, an average of 1 year

  5. immunogenicity

    number of subjects developing anti-MOR202 antibodies

    Time frame: through study completion, an average of 1 year

07

Study locations

25 sites
  • Managadze National Center of Urology
    Tbilisi, Georgia
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
    Tbilisi, Georgia
  • University Hospital Aachen
    Aachen, Germany
  • Charite
    Berlin, Germany
  • DaVita Clinical Research
    Düsseldorf, Germany
  • Uniklinikum
    Essen, Germany
  • Hospital of Johannes Gutenberg University
    Mainz, Germany
  • General Hospital of Athens
    Athens, Greece
  • General Hospital of Heraklion Venizeleio-Papaneio
    Heraklion, Greece
  • University General Hospital of Patras
    Patras, Greece
  • General Hospital of Thessaloniki
    Thessaloníki, Greece
  • Hallym University Sacred Heart Hospital
    Chuncheon, Korea, Republic of
  • JeJu National University Hospital
    Jeju, Korea, Republic of
  • Konkuk University Hospital
    Seoul, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Seoul, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seoul, Korea, Republic of
  • Botkin Hospital Moscow
    Moscow, Russian Federation
  • First Pavlov State Medical University of St. Petersburg
    Saint Petersburg, Russian Federation
  • Chang Gung Memorial Hospital
    Kaohsiung, Taiwan
  • Shuang Ho Hospital
    New Taipei City, Taiwan
  • China Medical University Hospital
    Taichung, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Kings College
    London, United Kingdom
  • Nottingham Renal and Transplant Unit
    Nottingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Dec 2023, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Feb 1, 2021
StartActual
Jan 20, 2021
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Results delay requested
Dec 10, 2024
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04733040
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Jan 20, 2021
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Last update
Feb 7, 2025

Study contacts

Medical Director
study director · HI-Bio, A Biogen Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion